LENSAR (LNSR)
Builds cataract laser systems and earns recurring revenue from procedures, leases, service, and consumables.
Something off on this page? Send us feedback.
Sells and leases LENSAR Laser System and ALLY cataract platforms for cataract treatment and astigmatism management. Revenue is tied to installed systems, procedure licenses, patient-interface devices, leases, service, and a business base weighted toward the United States.
Designs and commercializes ophthalmic laser systems used in cataract treatment and astigmatism management. The current portfolio includes the legacy LENSAR Laser System and ALLY, a compact robotic cataract laser platform that pairs laser capability with proprietary imaging and software.
Sells and leases systems, then earns recurring revenue from procedure licenses, patient-interface devices, service, and support. Product and service revenue is weighted toward the United States, while ALLY has availability or regulatory clearance across the United States, Europe, India, Taiwan, South Korea, and other markets.
Operates as a single reportable segment and continues independently after the terminated Alcon merger. Sales and leases tend to be stronger late in the year and slower early in the year, and tariff policies affect raw-material costs for ALLY systems and patient-interface devices.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Lake Street | Reiterate | Rating: —Target: — | Target: $13 |
| Mar 18, 2026 | BTIG | Upgrade | ||
| Mar 17, 2026 | BTIG | Target | Target: — | Target: $10 |
| Mar 24, 2025 | Lake Street | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.6M · Total debt $2.4M · Total assets $69.6M · Shareholders' equity $14.9M
- Revenue
- $16.5M
- Operating income
- $2.1M
- Net income
- $3.5M
No dividends on record.
| Institutions | 35.96% | 4.42M shares | |
|---|---|---|---|
| 80 holders · as of Jun 30, 2026 | |||
| Insiders | 24.18% | 2.97M shares | |
| 11 holders · as of Jun 5, 2026 | |||
| Other | 39.86% | 4.90M shares | |
| remainder | |||
12.29M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nicholas T. CurtisInsiderdirector, officer: Chief Executive Officer | 9.14% | 1.12M | filed Jun 5, 2026 |
Brandes Investment Partners, LPInstitution | 8.75% | 1.08M | as of Jun 30, 2026 |
Silver Point Capital, L.P.Institution | 8.14% | 999,789 | filed Oct 15, 2020 |
William J. Phd LinkInsiderdirector | 4.62% | 568,062 | filed Jun 5, 2026 |
Vanguard Capital Management LLCInstitution | 3.28% | 402,806 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Alcon
Direct FLACS rival through LenSx and cataract-surgery scale
- Johnson & Johnson
Direct FLACS rival through CATALYS and J&J Vision scale
- Bausch + Lomb
VICTUS and planned SeeLyra challenge cataract laser workflows
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LENSAR | $7.20 | −0.14% | $88.6M | — | — | 1.5 | −1.8% |
| Alcon | $65.42 | +0.85% | $31.64B | 49.9 | 17.2 | 2.9 | +7.5% |
| Johnson & Johnson | $269.68 | +0.08% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Bausch + Lomb | $17.23 | +2.56% | $6.00B | — | 17.3 | 1.1 | +9.1% |
| Median | 40.6 | 17.3 | 2.9 | +7.5% |